Cargando…
Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis
(1) Background: Systemic granulomatosis developed in a context of malignancy has already been reported. Our objective was to describe the clinical, radiological, functional, biological, and evolutive characteristics of sarcoidosis-like cancer-associated granulomatosis (SLCAG) and to compare them to...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124510/ https://www.ncbi.nlm.nih.gov/pubmed/34063172 http://dx.doi.org/10.3390/jcm10091988 |
_version_ | 1783693226040885248 |
---|---|
author | Pastré, Jean Bouvry, Diane Juvin, Karine Benattia, Amira Annesi-Maesano, Isabella Valeyre, Dominique Nunes, Hilario Israël-Biet, Dominique |
author_facet | Pastré, Jean Bouvry, Diane Juvin, Karine Benattia, Amira Annesi-Maesano, Isabella Valeyre, Dominique Nunes, Hilario Israël-Biet, Dominique |
author_sort | Pastré, Jean |
collection | PubMed |
description | (1) Background: Systemic granulomatosis developed in a context of malignancy has already been reported. Our objective was to describe the clinical, radiological, functional, biological, and evolutive characteristics of sarcoidosis-like cancer-associated granulomatosis (SLCAG) and to compare them to those of sarcoidosis. (2) Methods: 38 patients with a biopsy-proven SLCAG developed after a diagnostic of malignancy were included. The control group consisted of sarcoidosis patients matched for age, sex, and radiologic stage. Clinical, biological, physiological, radiological, and outcome data were collected. (3) Results: The mean age of SLCAG patients was 51 ± 14 years. They were diagnosed within 15 ± 14 months of the cancer diagnosis (breast cancer most frequently). All SLCAG patients presented a thoracic involvement, extrathoracic locations were observed in 32% of subjects. SLCAG was more often asymptomatic than sarcoidosis (p < 0.0001). During follow-up, systemic treatment was less often required in SLCAG than in sarcoidosis (58% vs. 32%, p = 0.04 respectively) and SLCAG were characterized by a significantly less severe progression profile according to the Sarcoid Clinical Activity Classification, with a complete recovery more frequent at 5 years (p = 0.03). (4) Conclusion: This case-control study shows that SLCAG differs from sarcoidosis with a significantly more benign course. These results might argue for true differences in the physiopathology, which remain to be elucidated. |
format | Online Article Text |
id | pubmed-8124510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81245102021-05-17 Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis Pastré, Jean Bouvry, Diane Juvin, Karine Benattia, Amira Annesi-Maesano, Isabella Valeyre, Dominique Nunes, Hilario Israël-Biet, Dominique J Clin Med Article (1) Background: Systemic granulomatosis developed in a context of malignancy has already been reported. Our objective was to describe the clinical, radiological, functional, biological, and evolutive characteristics of sarcoidosis-like cancer-associated granulomatosis (SLCAG) and to compare them to those of sarcoidosis. (2) Methods: 38 patients with a biopsy-proven SLCAG developed after a diagnostic of malignancy were included. The control group consisted of sarcoidosis patients matched for age, sex, and radiologic stage. Clinical, biological, physiological, radiological, and outcome data were collected. (3) Results: The mean age of SLCAG patients was 51 ± 14 years. They were diagnosed within 15 ± 14 months of the cancer diagnosis (breast cancer most frequently). All SLCAG patients presented a thoracic involvement, extrathoracic locations were observed in 32% of subjects. SLCAG was more often asymptomatic than sarcoidosis (p < 0.0001). During follow-up, systemic treatment was less often required in SLCAG than in sarcoidosis (58% vs. 32%, p = 0.04 respectively) and SLCAG were characterized by a significantly less severe progression profile according to the Sarcoid Clinical Activity Classification, with a complete recovery more frequent at 5 years (p = 0.03). (4) Conclusion: This case-control study shows that SLCAG differs from sarcoidosis with a significantly more benign course. These results might argue for true differences in the physiopathology, which remain to be elucidated. MDPI 2021-05-05 /pmc/articles/PMC8124510/ /pubmed/34063172 http://dx.doi.org/10.3390/jcm10091988 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pastré, Jean Bouvry, Diane Juvin, Karine Benattia, Amira Annesi-Maesano, Isabella Valeyre, Dominique Nunes, Hilario Israël-Biet, Dominique Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis |
title | Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis |
title_full | Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis |
title_fullStr | Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis |
title_full_unstemmed | Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis |
title_short | Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis |
title_sort | sarcoidosis-like cancer-associated granulomatosis: characteristics and a case-control comparison with sarcoidosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124510/ https://www.ncbi.nlm.nih.gov/pubmed/34063172 http://dx.doi.org/10.3390/jcm10091988 |
work_keys_str_mv | AT pastrejean sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis AT bouvrydiane sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis AT juvinkarine sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis AT benattiaamira sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis AT annesimaesanoisabella sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis AT valeyredominique sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis AT nuneshilario sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis AT israelbietdominique sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis |